December 2006 in “Lancet Oncology” In men aged 40–60 years with androgenic alopecia, this study found that 1 mg/day finasteride reduced serum PSA concentrations by 40-50% after 48 weeks compared to placebo.
April 2012 in “The Journal of Urology” This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.
1 citations
,
October 2009 in “Cancer Epidemiology Biomarkers & Prevention” This review discusses the American Society of Preventive Oncology's focus on cancer prevention and highlights the ongoing challenges and developments in screening, tobacco control, and the need for innovative risk-reduction strategies; it reports no new research findings.
March 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This study found that screening for prostate cancer did not significantly reduce prostate cancer-specific mortality in a meta-analysis of five randomized controlled trials, although one trial reported a benefit in a specific age subgroup.
3 citations
,
March 2007 in “Canadian Medical Association Journal” This abstract provides background information on polycystic ovary syndrome and reports no new research findings.
